On April 8, 2019 Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported that the company is scheduled to present an update on the company’s programs and progress at the following upcoming conferences (Press release, Trillium Therapeutics, APR 8, 2019, View Source [SID1234535037]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investor Conferences:

H.C. Wainwright Global Life Sciences Conference

Presenter: Dr. Niclas Stiernholm, Chief Executive Officer

Date and Time: April 9, 2019 at 3:10 p.m. BST

Location: Grosvenor House, London

18th Annual Needham Healthcare Conference

Presenter: Dr. Bob Uger, Chief Scientific Officer

Date and Time: April 10, 2019 at 12:00 p.m. ET

Location: Westin Grand Central Hotel, New York City

A live audio webcast of the H.C. Wainwright Global Life Sciences Conference presentation will be available under the investor relations section of Trillium’s website at www.trilliumtherapeutics.com.